Literature DB >> 18201985

Human immunodeficiency virus and tuberculosis in Argentina: prevalence, genotypes and risk factors.

Maria A Pando1, Cristina De Salvo2, Christian T Bautista3, Lindsay Eyzaguirre4, Gladys Carrion5, Miguel Feola6, Isabel Lado7, Marta Hoffman8, Mirna M Biglione9,1, Jean K Carr4, Silvia M Montano5, José L Sanchez10,11, Mercedes Weissenbacher9,1, Maria M Avila9,1.   

Abstract

The objective of this study was to determine the prevalence and genetic variability of human immunodeficiency virus type 1 (HIV-1) and other sexually transmitted infections (STIs) among 205 patients with clinical diagnosis of tuberculosis (TB) in Buenos Aires in 2001. Infections with hepatitis B virus (HBV), HIV-1, hepatitis C virus (HCV), Treponema pallidum and human T-cell lymphotropic virus types I/II were diagnosed in 37/187 (19.8 %), 35/205 (17.1 %), 22/187 (11.8 %), 13/187 (7.0 %) and 4/181 (2.2 %) patients, respectively. Almost one in three participants (33.1 %) presented at least one infection in addition to TB. Multiresistance to TB drugs (isoniazid plus rifampicin) was detected in the isolates recovered from three patients. Injecting drug use was detected as the main risk factor for HIV, HBV and HCV infections. Of ten patients who died, eight were infected with HIV. HIV genetic characterization showed the presence of two different subtypes. Env subtype F was found in 13/24 samples (54.2 %) and subtype B in 11/24 samples (45.8 %) by heteroduplex mobility assay. Sequencing of the protease/RT region was performed in ten samples: three were characterized as subtype B and seven as B/F recombinants by bootscanning analysis. Phylogenetic analysis of four full-length sequences showed that three were the circulating recombinant form CRF12_BF. The results of this study suggest an urgent need to detect HIV infection in high-risk groups to prevent future HIV transmission as well as morbidity and mortality associated with TB by providing highly active antiretroviral therapy (HAART) and/or TB treatment. Collaboration between TB and HIV programmes seems to be the best approach to decrease the incidence of these diseases, especially in high-prevalence HIV settings.

Entities:  

Mesh:

Year:  2008        PMID: 18201985     DOI: 10.1099/jmm.0.47492-0

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  7 in total

1.  Incidence of HIV type 1 infection, antiretroviral drug resistance, and molecular characterization in newly diagnosed individuals in Argentina: A Global Fund Project.

Authors:  M A Pando; M Gómez-Carrillo; M Vignoles; A E Rubio; M S dos Ramos Farias; M Vila; D Rossi; G Ralón; R Marone; E Reynaga; J Sosa; O Torres; M Maestri; M M Avila; H Salomón
Journal:  AIDS Res Hum Retroviruses       Date:  2010-09-23       Impact factor: 2.205

2.  IL-12 and GM-CSF in DNA/MVA immunizations against HIV-1 CRF12_BF Nef induced T-cell responses with an enhanced magnitude, breadth and quality.

Authors:  Ana María Rodríguez; María Fernanda Pascutti; Cynthia Maeto; Juliana Falivene; María Pía Holgado; Gabriela Turk; María Magdalena Gherardi
Journal:  PLoS One       Date:  2012-05-24       Impact factor: 3.240

3.  Prevalence of hepatitis C virus and human immunodeficiency virus in a group of patients newly diagnosed with active tuberculosis in Porto Alegre, Southern Brazil.

Authors:  Cintia Costi; Tarciana Grandi; Maria Laura Halon; Márcia Susana Nunes Silva; Cláudia Maria Dornelles da Silva; Tatiana Schäffer Gregianini; Lia Gonçalves Possuelo; Carla Adriane Jarczewski; Christian Niel; Maria Lucia Rosa Rossetti
Journal:  Mem Inst Oswaldo Cruz       Date:  2017-04       Impact factor: 2.743

4.  Identification of CRF89_BF, a new member of an HIV-1 circulating BF intersubtype recombinant form family widely spread in South America.

Authors:  Elena Delgado; Aurora Fernández-García; Marcos Pérez-Losada; María Moreno-Lorenzo; Ismael Fernández-Miranda; Sonia Benito; Vanessa Montero; Horacio Gil; Silvia Hernáez; Josefa Muñoz; Miren Z Zubero-Sulibarria; Elena García-Bodas; Mónica Sánchez; Jorge Del Romero; Carmen Rodríguez; Luis Elorduy; Elena Bereciartua; Esther Culebras; Icíar Rodríguez-Avial; María Luisa Giménez-Alarcón; Carmen Martín-Salas; Carmen Gómez-González; José J García-Irure; Gema Cenzual; Ana Martínez-Sapiña; María Maiques-Camarero; Lucía Pérez-Álvarez; Michael M Thomson
Journal:  Sci Rep       Date:  2021-06-01       Impact factor: 4.379

5.  HIV infection and geographically bound transmission of drug-resistant tuberculosis, Argentina.

Authors:  Viviana Ritacco; Beatriz López; Marta Ambroggi; Domingo Palmero; Bernardo Salvadores; Elida Gravina; Eduardo Mazzeo; Susana Imaz; Lucía Barrera
Journal:  Emerg Infect Dis       Date:  2012-11       Impact factor: 6.883

6.  Characterization of hepatitis C infection in tuberculosis patients in an urban city in the USA.

Authors:  M Campo; A Shrestha; E Oren; H Thiede; J Duchin; M Narita; K Crothers
Journal:  Epidemiol Infect       Date:  2013-09-25       Impact factor: 4.434

7.  Prevalence of Hepatitis C Virus in Tuberculosis Patients: A Systematic Review and Meta-Analysis.

Authors:  Meysam Behzadifar; Sanaz Heydarvand; Masoud Behzadifar; Nicola Luigi Bragazzi
Journal:  Ethiop J Health Sci       Date:  2019-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.